Alector Inc
ALEC1.550USD
+0.100+6.90%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
154.99MMarket Cap
LossP/E TTM
More Details of Alector Inc Company
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Company Info
Ticker SymbolALEC
Company nameAlector Inc
IPO dateFeb 07, 2019
CEODr. Arnon Rosenthal, Ph.D.
Number of employees238
Security typeOrdinary Share
Fiscal year-endFeb 07
Address131 Oyster Point Blvd., Suite 600
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone14152315660
Websitehttps://alector.com
Ticker SymbolALEC
IPO dateFeb 07, 2019
CEODr. Arnon Rosenthal, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.58M
+2.52%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
156.08K
+53.99%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
53.91K
+113.85%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Mr. Giacomo Salvadore, M.D.
Mr. Giacomo Salvadore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Louis J. (Lou) Lavigne, Jr.
Mr. Louis J. (Lou) Lavigne, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Errol De Souza, Ph.D.
Dr. Errol De Souza, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.58M
+2.52%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
156.08K
+53.99%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
53.91K
+113.85%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.39%
Polaris Venture Partners
9.85%
RA Capital Management, LP
9.70%
BlackRock Institutional Trust Company, N.A.
6.41%
The Vanguard Group, Inc.
6.05%
Other
53.59%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.39%
Polaris Venture Partners
9.85%
RA Capital Management, LP
9.70%
BlackRock Institutional Trust Company, N.A.
6.41%
The Vanguard Group, Inc.
6.05%
Other
53.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.87%
Venture Capital
21.09%
Investment Advisor/Hedge Fund
13.63%
Hedge Fund
8.42%
Individual Investor
7.06%
Corporation
3.55%
Research Firm
2.88%
Pension Fund
0.22%
Bank and Trust
0.08%
Other
8.20%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
372
91.63M
91.64%
-20.36M
2025Q1
390
94.05M
94.69%
-22.49M
2024Q4
384
95.68M
96.58%
-16.24M
2024Q3
380
93.59M
96.08%
-7.82M
2024Q2
378
93.92M
97.44%
-5.66M
2024Q1
379
96.98M
102.83%
+4.66M
2023Q4
382
85.51M
101.07%
-5.87M
2023Q3
384
84.61M
100.28%
-2.32M
2023Q2
384
80.93M
96.65%
-6.40M
2023Q1
391
80.04M
96.46%
-3.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
14.39M
14.39%
-299.63K
-2.04%
Mar 31, 2025
Polaris Venture Partners
9.85M
9.85%
--
--
Sep 30, 2024
RA Capital Management, LP
9.70M
9.7%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.41M
6.41%
-393.95K
-5.79%
Mar 31, 2025
The Vanguard Group, Inc.
6.05M
6.05%
+453.75K
+8.10%
Mar 31, 2025
Rosenthal (Arnon)
5.44M
5.44%
-52.09K
-0.95%
Jun 02, 2025
Merck & Co Inc
3.55M
3.55%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
1.96%
+47.85K
+2.50%
Mar 31, 2025
State Street Global Advisors (US)
1.64M
1.64%
-209.03K
-11.30%
Mar 31, 2025
J.P. Morgan Securities LLC
1.45M
1.45%
-159.71K
-9.94%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares Neuroscience and Healthcare ETF
0.27%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Biotechnology ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
JPMorgan Fundamental Data Science Small Core ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
iShares Neuroscience and Healthcare ETF
Proportion0.27%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
